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ABSTRACT
The purpose of this article was to examine historic institutional autologous stem cell mobilization practices and
evaluate factors influencing mobilization failure and kinetics. In this retrospective study we analyzed clinical re-
cords of 1834 patients who underwent stem cell mobilization for autologous transplantation from November
1995 to October 2006 at the Washington University in St. Louis. Successful mobilization was defined as collec-
tion of $2  106 CD341 cells/kg. From 1834 consecutive patients, 1040 met our inclusion criteria (502 non-
Hodgkin’s lymphoma [NHL], 137 Hodgkin’s lymphoma, and 401 multiple myeloma [MM]). A total of 976
patients received granulocyte colony-stimulating factor (G-CSF) and 64 received G-CSF plus chemotherapy
(G/C) for the initial mobilization. Although the median CD341 cell yield was higher in G/C group than in
G-CSF alone group, the failure rates were similar: 18.8% and 18.6%, respectively. Overall, 53% of patients col-
lected $2  106 CD341 cells/kg during the first apheresis with either mobilization regimen. Regardless of mo-
bilization regimen used, MM patients had the highest total CD341 cell yield and required less aphereses to
collect $2  106 CD341 cells/kg. Mobilized, preapheresis, peripheral blood CD341 count correlated with first
day apheresis yield (r5 .877, P\ .001) and 20 cells/mLwas the minimum threshold needed for a successful day 1
collection. For the remobilization analysis we included patients from the whole database. A total of 269 of 1834
patients underwent remobilization using G/C, G-CSF, and/or GM-CSF, and G-CSF plus plerixafor. Only 23%
of remobilized patients achieved $2  106 CD341 cells/kg and 29.7% failed to pool sufficient number of stem
cells from both collections. Patients receiving G-CSF plus plerixafor had lowest failure rates, P5 .03. NHL pa-
tients remobilized with G-CSF who waited $25 days before remobilization had lower CD341 cell yield than
those who waited #16 days, P 5 .023. Current mobilization regimens are associated with a substantial failure
rate irrespective of underlying disease. Patients who fail initial mobilization aremore likely to fail remobilization.
These findings suggest that there is a need for more effective first-line mobilization agents.
 2008 American Society for Blood and Marrow Transplantation
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High-dose chemotherapy, in conjunction with au-
tologous stem cell transplantation (ASCT), has
emerged as a preferred treatment modality for a variety
of hematologic malignancies including multiple mye-
loma (MM), non-Hodgkin’s lymphoma (NHL), andHodgkin’s lymphoma (HL) [1-3]. Multiple random-
ized trials have demonstrated the advantage of mobi-
lized peripheral blood stem cells (PBSC) over the
bone marrow for ASCT [4-6]. The collection of ade-
quate number of CD341 cells, a surrogate marker of
hematopoietic stem cells, is paramount because the1045
1046 I. Pusic et al.dose of infused CD341 cells influences the success and
rate of hematopoietic recovery [7-10]. There is evi-
dence to support that a ‘‘minimum’’ dose of 2  106
CD341 cells/kg is needed to ensure successful hema-
topoietic recovery and sustained engraftment
[11-14]. Recent studies have suggested that the ‘‘opti-
mal’’ dose, $5  106 CD341 cells/kg, results in more
rapid and predictable hematopoietic and, especially,
platelet recovery [15-18]. However, it may be difficult
to collect this yield in older and heavily pretreated
patients.
The 2most commonly usedmobilization regimens
are the cytokine granulocyte colony-stimulating factor
(G-CSF) and G-CSF plus chemotherapy (G/C).
G-CSF induces marrow hyperplasia and subsequent
release of stem cells into the circulation. Mobilization
is mediated in part through proteases that disrupt in-
teractions between adhesion molecules expressed on
stem cell surface and their ligands on bone marrow
stroma, and in part by nonproteolytic mechanisms reg-
ulating molecular expression of stromal cell-derived
factor-1 (SDF-1) at the mRNA level [19-24]. A signif-
icant proportion of patients mobilized with G-CSF
alone fail to collect the minimum number of CD341
cells to support ASCT, largely because of prior cyto-
toxic chemotherapy and advanced age [25,26]. Addi-
tion of chemotherapy to G-CSF is thought to induce
marrow aplasia, which subsequently stimulates hema-
topoietic recovery. It is speculated that the concomi-
tant use of chemotherapy and G-CSF might have
a synergistic effect on protease release in the bonemar-
row [27]. A novel small molecule, chemokine receptor-
4 (CXCR4) antagonist, AMD3100 (Plerixafor), has
been tested in the clinic and found to enhance mobili-
zation when administered with G-CSF [28-33].
Failure rates with current mobilization regimens
are estimated to be between 5% and 30% [15,34,35].
An unsuccessful initial mobilization attempt results
in additional mobilizations, which negatively impact
patients’ outcomes and significantly increase health
care utilization. The purpose of this retrospective anal-
ysis is to examine the efficacy of mobilization with
G-CSF alone and in combination with chemotherapy
in achieving minimal and optimal stem cell targets,
and to evaluate mobilization kinetics. We further cor-
relate peripheral blood CD341 cell count/mL before
mobilization and immediately prior to the first apher-
esis with mobilized CD341 cell/kg yield. Finally, we
evaluate the impact of various mobilization regimens
on the success of remobilization.
PATIENTS AND METHODS
Patient Population
This is a single-center retrospective analysis of the
clinical records in the ASCT database at Washington
University in St. Louis from November 1995 throughOctober 2006. Patient records were included if pa-
tients had MM, NHL, or HL, and had at least 1
PBSC mobilization attempt using G-CSF alone or
G/C. Patient records were excluded if patients had
solid tumors or leukemia, and first mobilization using
agents other than G-CSF or G/C. However, when
evaluating remobilization results we included patient
records from the whole database.
Mobilization Regimens
Initial mobilization regimens included G-CSF and
G/C. Patients mobilized with G-CSF alone received
G-CSF at 10 mg/kg/day subcutaneously (s.c.) for 4
days prior to apheresis. Aphereses and G-CSF were
continued daily for up to 5 consecutive days or until
$2  106 CD341 cells/kg were collected. The use
and selection of chemotherapy, as part of mobilization
regimen, depended on the patient’s diagnosis, clinical
status, and the preference of the treating physician. Pa-
tients mobilized with G/C started G-CSF at 10 mq/kg/
day s.c. on day 4 after chemotherapy and continued un-
til aphereses were completed. Apheresis started based
on the total white blood cell count .5000  106/L.
First mobilization was defined as no prior mobilization
attempt within 1 year. Mobilization failure was defined
as\2  106 CD341 cells/kg obtained within 5 apher-
esis days. Patients who failed initial mobilization were
remobilized after 10-30 days. Remobilization regi-
mens included G-CSF and/or granulocyte-macro-
phage colony-stimulating factor (GM-CSF), G/C,
and G-CSF plus plerixafor (G/P). When used in com-
bination with G-CSF, the dose of GM-CSF was 5 mg/
kg/day s.c. GM-CSF was started 5 days prior to apher-
esis (1 day prior to G-CSF) and continued daily, 30
min to 1 hour after G-CSF, until target goal CD341
was met or total of 5 aphereses. Patients mobilized
with G/P received G-CSF at 10 mg/kg/day s.c. every
morning for 4 days and on the evening of the fourth
day they received plerixafor at 240 mg/kg s.c. The
aphereses were started on day 5, after the morning
dose of G-CSF. Patients continued receiving their
morning dose of G-CSF and evening dose of plerixafor
until collected CD341 cell count was $2  106/kg or
total of 5 aphereses.
Apheresis and CD341 Cell Enumeration
Aphereses were performed using continuous-flow
blood cells separator (COBE Spectra, Lakewood,
CO) processing 18 to 20 L of blood during each pro-
cedure. Estimation of CD341 cell content in periph-
eral blood and in the apheresis product was
performed by flow cytometry using fluorescein-conju-
gated antihuman CD34 monoclonal antibody (anti-
HPCA-2, Becton Dickinson, San Jose, CA) [36,37].
The harvested product was cryporeserved in 10%
DMSO and Plasma-Lyte-A (Baxter, Deerfield, IL).
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Neutrophil engraftment was defined as the first of
3 consecutive days with absolute neutrophil count
$0.5  109/L without growth factor support, and
platelet engraftment as the first of 7 consecutive days
with platelet count$20 109/L without transfusions.
Statistical Analysis
Descriptive statistics were used to identify the pro-
portion of patients achieving minimal and optimal
CD341 cell collection, andmobilization failure by dis-
ease and mobilization regimen. Inferential statistical
testing was performed on the median total apheresis
yield between diseases using Kruskal-Wallis with
Dunn’s posttest. Chi-square test or Fisher’s exact test
when appropriate was used to compare mobilization
failure between different regimens. Time to hemato-
poietic recovery was estimated using the Kaplan-Meier
product-limit method and the log-rank test. The
Spearman rank correlation was used to test the associ-
ation of first-day apheresis CD341 cell yield with rest-
ing and mobilized peripheral blood CD341 cell count.
Statistical significance was set at P\ .05. Descriptive
and inferential statistics were performed using Graph-
Pad Prism.
RESULTS
Patient Populations and Demographics
The Washington University ASCT database con-
tained 2132 mobilization cases including 1834 cases
of first mobilization and 298 of remobilization. An
overview of the database is provided in Figure 1.
Among 1834 first mobilizers, 1040 patients (56.7%)
met our inclusion criteria: 502 cases ofNHL, 137 cases
of HL, and 401 cases of MM. 976 (93.8%) patients
were initially mobilized withG-CSF and 64 (6.2%) pa-
tients with G/C. Patient characteristics are presentedin Table 1. NHL and HL were analyzed together be-
cause these patients have similar previous treatments.
The only significant difference within the disease
groups was that MM patients with more advanced dis-
ease and a longer period from last treatment to first
mobilization were more likely to receive G/C. For
the remobilization analysis we included patients from
the whole database. The database contained 298 cases
of remobilization for 269 patients (29 patients were
mobilized a third time).
CD341 Cell Yield and Failure Rates
Overall 81.3% (846 of 1040) of patients collected
$2 106 CD341 cells/kg after a maximum of 5 apher-
eses, 52.7% (548 of 1040) collected 2-5  106 CD341
cells/kg, and 28.7% (298 of 1040) collected .5  106
CD341 cells/kg (Figure 2A).When cell collection out-
comes were compared by mobilization regimens, the
failure rate with G-CSF alone was 18.6% (182 of
976) and withG/Cwas 18.8% (12 of 64), P5 .984. De-
spite similar failure rates, more patients receiving G/C
collected .5  106 CD341 cells/kg than patients re-
ceiving G-CSF alone (56.3% versus 26.8%, respec-
tively, P\ .001). The median CD341 cell yield was
higher in patients receiving G/C than those receiving
G-CSF alone (5.43 106 and 3.36 106, respectively).
In addition, there was no difference in failure rates
within each disease group with either mobilization
regimen (Figure 2B and Table 2). Using G/C, more
patients collected the optimal count in all 3 diseases.
Patients with MM had the highest total CD341 cell
yield regardless of mobilization regimen.
Apheresis Kinetics
Among the patients who were successfully mobi-
lized, approximately 53% collected $2  106
CD341 cells/kg on the first apheresis day. A total of
77.7% of patients mobilized with G-CSF reachedStem Cell Mobilization Regimen
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Figure 1. Overview of autologous stem cell transplantation database by disease and by mobilization regimens; first mobilization (N 5 1834),
remobilization (N 5 298). NHL (non-Hodgkin’s lymphoma), HL (Hodgkin’s lymphoma), G-CSF (granulocyte colony-stimulating factor);
GM-CSF (granulocyte-macrophage colony-stimulating factor), Synthokine (modified human Interleukin-3/IL-3), MPO (Myelopoietin,
a G-CSF-IL-3 fusion protein).
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NHL/HL MM
G/C G-CSF P-value G/C G-CSF P-value
Number of Patients 47 592 17 384
Median Age (years) 51 53 56 57
Gender, n (%)
Male 28 (59.6) 354 (59.8) .9761 12 (70.5) 231 (60.2) .3890
Female 19 (40.4) 238 (40.2) 5 (29.5) 153 (39.8)
Disease Status, n (%)
CR/ PR # 1 14 (29.8) 223 (37.7) .5488 13 (76.5) 346 (90.1) .0004
CR/ PR 5 2 24 (51.1) 274 (46.3) 3 (17.6) 38 (9.9)
CR/ PR $ 3 9 (19.1) 95 (16.0) 1 (5.9) 0
Prior radiotherapy 14 (29.8) 97 (16.4) .0196 7 (41.2) 192 (50.0) .5697
Number of prior chemotherapy regimens*
1 17 (37.0) 130 (22.0) .0659 13 (76.4) 230 (59.8) .3379
2 22 (47.8) 357 (60.3) 3 (17.6) 134 (35.0)
$ 3 7 (15.2) 105 (17.7) 1 (6.0) 20 (5.2)
Time from last chemotherapy to mobilization
1 to 2 months 40 (87.0) 531 (89.7) .4056 9 (53.0) 346 (90.2) \.001
2 to 3 months 5 (10.9) 37 (6.2) 4 (23.5) 19 (4.9)
.3 months 1 (2.1) 24 (4.1) 4 (23.5) 19 (4.9)
Chemomobilization
Cyclophosphamide 3 (6.4) — 17 (100%) —
Ara-C 1 Etoposide 12 (25.5) — 0 —
ESHAP/ DSHAP 14 (29.8) — 0 —
ICE/ RICE 13 (27.6) — 0 —
Others 5 (10.6) — 0 —
NHL indicates non-Hodgkin’s lymphoma; HL, Hodgkin’s lymphoma; MM, multiple myeloma; G-CSF, granulocytecolony-stimulating factor;
G/C, G-CSF 1 chemotherapy; CR, complete remission; PR, partial remission; ICE, ifosfamide, carboplatin, etoposide; ESHAP/DHAP,
etoposide, cytarabine, methylprednisolone, cisplatine/cytarabine, dexamethasone, cisplatin.
*OneNHLpatient in theG-CSF and chemotherapymobilization group did not receive any therapy prior tomobilization andwas not included in
the disease status evaluation and prior chemotherapy evaluation.this minimum target within the first 2 days, compared
with 75.0%mobilized with G/C (P5NS; Figure 2C).
This pattern of apheresis was observed across all 3 dis-
eases (Figure 2D). G/C significantly increased the per-
centage of patients reaching the minimumCD341 cell
count on the first apheresis day only in MM (63.6%
with G-CSF and 93.8% with G/C, P5 .013). The me-
dian number of aphereses to achieve$2 106 CD341
cells/kg was significantly greater amongNHL andHL
patients than MM (2 and 1, respectively, P\ .01).
Peripheral CD341 Cell Counts
Mobilized, preapheresis, peripheral blood CD341
cell count was found to be a significant predictor of day
1 CD341 cell collection regardless of the underlying
disease or mobilization regimen (P \ .0001, r .
.899; Figure 3A). Additionally, we identified the mini-
mum of 20 mobilized peripheral blood CD341 cells/
mL required for a successful day 1 collection. 54.2%
(529 of 976) of G-CSF mobilized patients and 58.1%
(36 of 62) of G/C mobilized patients had peripheral
blood CD341 cells count .20 cells/mL on day 1 im-
mediately prior to the first apheresis. This is consistent
with percentage of patients collecting $2  106
CD341 on the first apheresis day (53.1% for G-CSF
and 54.7% for G/C; Figure 2C). Premobilization,steady-state peripheral blood CD341 cell count corre-
lated poorly with the first day apheresis yield for all 3
diseases (r\ .54; Figure 3B).
Engraftment
The relationship between the dose of infused
CD341 cells and engraftment was analyzed. Infusion
of .10  106 CD341 cells/kg was associated with
a shorter time to neutrophil and platelet engraftment
than was a cell dose of \2  106 CD341 cells/kg
(P\ .01). There were no differences in time to either
platelet or neutrophil recovery among the different
mobilization regimens used.
Remobilization
A total of 350 of 1834 patients failed initial mobi-
lization but only 269 of 350 patients were remobilized.
Following remobilization, only 62 (23.0%) patients
achieved $2  106 CD341 cells/kg. The failure rates
following remobilization with G-CSF and/or GM-
CSF, G/C, and G/P were 81.6%, 73.5%, and 27.8%,
respectively, P\ .001 (Table 3).
We further examined the impact of wait time be-
tween first mobilization and remobilization on the re-
mobilization failure rate. The time between the first
and second mobilization was segregated into quartiles.
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Figure 2. (A) Distribution of total CD341 cells/kg yield within 5 apheresis days after the first mobilization. Total number of patients analyzed
was 1040; 976mobilized withG-CSF and 64 withG/C. (B) CD341 cell/kg yield by disease and bymobilization regimens. (C) Duration of apher-
esis to collect$2  106 CD341 cells/kg for successfully mobilized patients. Total number of successfully mobilized patients was 846; 794 mo-
bilized with G-CSF and 52 with G/C. (D) Duration of apheresis to collect $2  106 CD341 cells/kg in different diseases for successfully
mobilized patients. Total number of successfully mobilized patients was 846; 794 mobilized with G-CSF and 52 with G/C. NHL (non-Hodg-
kin’s lymphoma), HL (Hodgkin’s lymphoma), MM (multiple myeloma), G-CSF (granulocyte colony-stimulating factor), G/C (G-CSF 1
chemotherapy).
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Figure 2. (Continued)
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longest was $25 days. NHL patients remobilized
with G-CSF who waited $25 days before remobiliza-
tion had lower CD341 cell yield than those who waited
#16 days, (P 5 .023; Figure 4).
When cells from the first and second mobilization
were pooled, 169 patients (62.8%) collected 2-5  106
CD341 cells/kg and 20 patients (7.4%) collected .5
 106 CD341 cells/kg. Importantly, 80 patients
(29.7%) failed to pool sufficient number of cells from
the first and second mobilization to proceed to trans-
plantation. Among remobilization regimens, G/C
had the highest pooled failure rates (47.1%) compared
to G-CSF 6 GM-CSF (28.1%) and G/P (16.7%)
(P 5 .03; Table 3). Remobilization with G/P had the
lowest failure rate, both after second mobilization
alone and after pooling the cells from the first and
second collections.
DISCUSSION
An ideal mobilization regimen should allow for
predictable and reliable collection of sufficient
CD341 cells for transplantation, have limited toxicity,
and result in prompt and durable engraftment. The
findings from this retrospective study, however, dem-
onstrate that our current mobilization regimens are
far from ideal. Although mobilization regimens con-
taining G/C resulted in significantly higher CD341
cell yield and higher percentage of patients reaching
the optimal CD341 cell count than regimens using
G-CSF alone, the failure rates for initial mobilization
were not different between the 2 mobilization groups.
In addition, the failure rates with either mobilization
regimen were nearly identical within each disease
group. When failure rates were compared among dif-
ferent diseases, patients with NHL and HL had ap-
proximately 4-fold higher failure rates, with either
mobilization regimen, than patients with MM. Both
Table 2. First Mobilization Failure Rates and CD341 Cell Yields by
Disease and by Regimen
CD341 Cell Yield†
(106 cells/kg)
Disease Mobilization N
Failure*
(%) Median (range)
NHL (n 5 502) G-CSF 467 26.8% 2.9 (2.8-3.0)
G/C 35 22.9% 4.7 (2.8-8.5)
HL (n 5 137) G-CSF 125 26.4% 3.0 (2.8-3.4)
G/C 12 25.0% 4.7 (1.0-9.5)
MM (n 5 401) G-CSF 384 6.3% 4.6 (4.2-5.0)
G/C 17 5.9% 8.5 (4.5-16.3)
NHL indicates non-Hodgkin’s lymphoma; HL, Hodgkin’s lym-
phoma; MM, multiple myeloma; G-CSF, granulocytecolony-
stimulating factor; G/C, G-CSF 1 chemotherapy.
*NHL: P 5 .61; HL: P 5 .92; MM: P 5 .95.
†P\ .01 compared between G-CSF and G/C for all diseases.mobilization regimens had a similar collection pattern,
with over 75% of successfully mobilized patients col-
lecting the minimum CD341 dose within the first 2
apheresis days. CD341 cell yield declined significantly
after second collection, suggesting that there is little
benefit in extending apheresis beyond the first 2 days.
In our study, only 56.3% of patients in G/C group
and 26.8% in G-CSF group achieved the optimal
CD341 cells target of 5 106 cells/kg after 5 apheresis
days. When the total CD341 cell yields were com-
pared among different disease groups, MM patients
had higher yield compared toNHL andHL regardless
of the mobilization regimens, likely because of the fact
that NHL and HL patients are frequently more
heavily pretreated with cytotoxic chemotherapy than
patients with MM. Recent data suggests that this
may not be the case in MM patients treated prior to
stem cell harvest with lenalidomide containing therapy
[38]. It should be noted that none of the MM patients
in our database received lenalidomide prior to mobili-
zation. Because of the higher yield of CD341 cells col-
lected per apheresis inMM patients mobilized with G/
C, such regimens might be useful in preparation for
tandem ASCT.
It was initially thought that chemotherapy as a part
of mobilization regimen might reduce tumor contam-
ination in the apheresis product. Although tumor con-
tamination might be reduced by the addition of
chemotherapy, it does not appear to have any effect
on relapse rate or survival [39,40]. Chemotherapy con-
taining mobilization regimens are associated with in-
creased risk for secondary malignances, impaired
fertility, cardiac toxicity, risk of cytopenias and infec-
tions, resulting in increased resource use and cost
[41-44]. In addition, such regimens have a less predict-
able collection schedule; thus, the potential to delay
the transplant, resulting in increased morbidity and
mortality. Because of these potential risks, the routine
addition of chemotherapy to G-CSF for mobilization
may not be justified. Several randomized studies
compared mobilization using G-CSF alone with G/C
[42,45,46]. Although these studies were relatively
small, they showed that despite the higher yield of
CD341 cells collected in G/C groups, mobilization
with G-CSF alone resulted in adequate CD341 cell
collections with lower toxicity and cost.
Many variables have been previously reported to
be associated with successful mobilization including
peripheral blood white cell count, platelet count,
peripheral blood CD341 cell count prior to mobiliza-
tion, the number of days after chemotherapy adminis-
tration, and other patient factors [26,47-50]. However,
none of these factors alone are predictive of CD341
cell collection. We observed that mobilized, preaphe-
resis, peripheral blood CD341 cell count is strongly
associated with day 1 CD341 cell yield regardless of
underlying disease or mobilization regimen. Until
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Figure 3. (A) Correlation between mobilized preapheresis peripheral blood CD341 cell count with day 1 apheresis yield. (B) Correlation of pre-
mobilization peripheral bloodCD341 cell count with day 1 apheresis yield.NHL (non-Hodgkin’s lymphoma), HL (Hodgkin’s lymphoma),MM
(multiple myeloma), G-CSF (granulocyte colony-stimulating factor), G/C (G-CSF 1 chemotherapy).
Impact of Mobilization Strategies on Stem Cell Yields 1053there are other reliable and predictable markers for
successful collection, mobilized peripheral blood
CD341 cell count may be the only reliable way of
determining if the patient should undergo apheresis.
In our database 350 patients failed initial mobili-
zation but only 269 (77%) of those were remobilized.
Table 3. Outcomes of Remobilization
G-CSF / GM-CSF G/C G/P
Remobilization
regimen used N 5 217 N 5 34 N 5 18
First mobilization
with G-CSF
Median CD341
cell/kg yield
1.1  106 0.8  106 1.0  106
Median apheresis
days
4 days 3 days 2.5 days
Remobilization
Median CD341
cell/kg yield
1.2  106 0.9  106 4.6  106
Median apheresis
days
3 days 2 days 2.5 days
Failure rate* 81.6% 73.5% 27.8%
Pooled cells
(first and second
mobilization)
Median CD341
cell/kg yield
2.5  106 2.1  106 5.5  106
Median apheresis
days
6 7 6
Overall failure
rate†
28.1% 47.1% 16.7%
G-CSF indicates granulocytecolony-stimulating factor; G/C, G-
CSF 1 chemotherapy.
*P # .001 comparison among all 3 groups.
†P 5 .03 comparison among all 3 groups.
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Figure 4. Impact of wait time between first and second mobilization
on apheresis yield in NHL (non-Hodgkin’s lymphoma) patients re-
mobilized with G-CSF (granulocyte colony-stimulating factor);
Box-Whiskers graphs compares the median CD34/kg yields from
the lowest wait time quartile (\16 days) to the quartile with the lon-
gest wait time to remobilization (.25 days).The remaining 23% of patients were never mobilized
again, progressed, and were not candidates for
ASCT, or proceeded to allogeneic stem cell trans-
plantation. When collections from the first and sec-
ond mobilizations were pooled, approximately 30%
of patients failed to collect sufficient cells for trans-
plantation, and this was universal across all diseases.
This represents another 80 patients who either pro-
gressed or were exposed to the risks of allogeneic
transplantation. All of these alternatives dramatically
increase the risk of early morbidity and mortality,
emphasizing again the need to achieve a minimum
yield of 2  106 CD341 cells /kg during the first mo-
bilization attempt. We observed that patients who
failed initial mobilization were likely to fail remobili-
zation regardless of mobilization regimen and under-
lying disease.
The timing between first and second mobilization
influenced remobilization outcomes in NHL patients
mobilized with G-CSF. Surprisingly, a longer wait
time between the first and second mobilization was as-
sociated with a worse mobilization outcome. This was
an unexpected finding which was not seen in ‘‘good
mobilizing’’ myeloma group where early or delayed re-
mobilization resulted in similar stem cell yields (data
not shown). These data demonstrate the lack of an ad-
vantage of waiting to remobilize versus proceeding as
early as possible in both NHL and MM patients.
The benefit of early remobilization seen in NHL pa-
tients may be because of multiple factors including
less infection, less disease progression, reduced expo-
sure to marrow suppressing drugs, and changing dy-
namics of bone marrow recovery after initial
mobilization attempt.
Plerixafor, a direct inhibitor of the interaction be-
tween the chemokine SDF-1 and its receptor CXCR4,
is a new and promising agent being studied alone or in
the conjunction withG-CSF for stem cell mobilization
[28-33,51,52] Flomenberg et al. [33] compared mobi-
lization withG-CSF andG/P in patients withMM and
NHL. All patients underwent 2 mobilizations, 1 using
G-CSF as a single agent and another usingG/P. For all
patients, G/P mobilized more CD341 cells per apher-
esis, required fewer aphereses and mobilized a higher
total yield of CD341 cells/kg. Cashen et al. [29]
reported successful mobilization of stem cells using
G/P in heavily pretreated HL patients. In our retro-
spective analysis remobilization with G/P had the low-
est failure rate, both after second mobilization alone
and after pooling the cells from the first and second
collections. This is similar to the compassionate use
program experience where G/P was successfully used
in patients who failed initial mobilization attempts
using different mobilization regimens [28]. Two phase
III, multicenter, randomized, double-blind, placebo-
controlled studies comparing G/P with G-CSF for
mobilization of stem cells in patients with MM and
1054 I. Pusic et al.NHL have shown that patients mobilized with G/P
were significantly more likely to achieve the target
CD341 cell count with fewer aphereses [51,52].
Consistent with other studies [15-18], we found
that patients transplanted with .10  106 CD341
cells/kg had faster neutrophil and platelet recovery
than patients receiving\2  106 CD341 cells. This
target of CD341 cells might be difficult to achieve
with current mobilization regimens. In addition, we
found no significant difference in platelet or neutro-
phil engraftment among groups receiving G-CSF
alone versus G/C, similar to randomized studies
comparing those 2 mobilization regimens
[42,45,46,53].
In summary, this study shows that current mobili-
zation regimens are far fromoptimal. It is to our knowl-
edge the largest retrospective study comparing success
of initial mobilization with G-CSF versus G/C and an-
alyzing remobilization strategies on achieving mini-
mum stem cell yields for autologous transplantation.
Although the number of patients who received G/C
was limited, it still represents a significant number of
patients studied and provides an insight into current
clinical practices. A better understanding of variables
associated with mobilization success and kinetics may
further optimize stem cell collection and reduce
complications associated with ASCT. It is clear that
addition of chemotherapy to G-CSF does not have
a significant impact on reaching the minimum target
necessary for proceeding to ASCT in patients with
MM, NHL, and HL. Although optimal yields occur
more often, G/C has no advantage over G-CSF alone
to reduce failure rates for stem cell mobilization. Iron-
ically, there appears to be no benefit in adding chemo-
therapy to G-CSF for remobilization. New strategies
are needed to minimize initial mobilization failure
rates, especially in patients at high risk for failure, and
allow collection of adequate number of stem cells in
a timely and predictable manner.
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